19
Aug

New Phase 1 Clinical Trial to Test Durvalumab in Pediatric Patients

In an innovative, order first-in-pediatrics study, ask available only at Children’s Hospital Los Angeles (CHLA), researchers will be enrolling children between 1 and 18 years of age who have certain types of relapsed or treatment-resistant cancer.

The aim of this investigator-initiated Phase 1 trial is to test the safety, tolerability and metabolism of the drug Durvalumab in pediatric patients with solid tumors, lymphoma and central nervous system tumors.

Durvalumab, which is also being investigated in several types of adult cancer, is what is known as a checkpoint inhibitor. A “checkpoint” is a molecule that is activated or inactivated to allow the body’s immune system to attack foreign cells while leaving normal cells alone.  Cancer cells often find ways to evade these checkpoints to avoid being attacked by the immune system.

Read Full Article Here >>